HCV: SOF/VEL/VOX yields sustained PRO gain

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • HCV treatment with sofosbuvir/velpatasvir (SOF/VEL) ± voxilaprevir (VOX) yields continued gain in patient-reported outcomes (PRO) after end of treatment.

Why this matters

  • PRO benefit was similar for SOF/VEL/VOX vs SOF/VEL.

Study design

  • PRO data from phase 3 POLARIS-2 and POLARIS-3 randomized trials of SOF/VEL/VOX (n=611) vs SOF/VEL (n=549).
  • PRO scale of 1-100 included domains from the Short Form-36 version 2 survey, Functional Assessment of Chronic Illness Therapy, Chronic Liver Disease Questionnaire-Hepatitis C Version, and Work Productivity and Activity Impairment Instrument: Specific Health Problem.
  • Funding: Gilead Sciences.

Key results

  • Mean age was 52.2 years; 55.9% of patients were male, 75.4% were treatment-naïve, and 33.9% had cirrhosis.
  • Rate of sustained virologic response at 12 weeks posttherapy ranged from 95%-98%.
  • Gastrointestinal adverse events were more common with SOF/VEL/VOX (29.6% vs 14.8%; P<.0001>
  • PRO scores improved significantly in 22/26 domains by end-of-treatment (mean Δ, +2.3 to +15.0); benefit was similar for SOF/VEL/VOX vs SOF/VEL (all P>.05).
  • All but 1 PRO measure (absenteeism) showed significant (P<.001 continued gain at post-treatment week to and>
  • PRO improvements were similar or more pronounced in patients with cirrhosis (post-treatment week 24, +4.4 to +23.5).

Limitations

  • Open-label design.